Articles tagged with Alzheimer Disease
A study by Purdue University and Mount Sinai School of Medicine found that chronic consumption of polyphenols from grapeseed extract can improve absorption in the brain, potentially preventing the formation of beta-amyloid protein associated with Alzheimer's disease. This research may lead to more effective treatment options for patients.
A large multicentre study has confirmed that a combination of proteins in the cerebrospinal fluid can reliably identify patients with early symptoms of dementia who will later develop full-blown Alzheimer's disease. The findings may lead to new medicines and point-of-care diagnostics.
A new observational study found that being physically active and adhering to a Mediterranean-type diet are associated with reduced risk of Alzheimer's. The study, published in the Journal of the American Medical Association, followed 1880 elderly subjects over five and a half years.
Researchers at UCLA have discovered that larger clusters of Amyloid β-protein are more toxic to nerve cells, but smaller clusters outnumber them and are more common. This finding provides a new target for therapeutic drug development.
A recent animal model study found that exposure to high concentrations of oxygen hastens memory loss in Alzheimer's mice. The study suggests that the combination of brain beta amyloid and hyperoxia may trigger Alzheimer's symptoms, particularly in those at increased risk. Researchers propose reducing oxygen exposure as a potential prev...
Elderly individuals with a Mediterranean diet rich in fruits, vegetables, and fish, and high levels of physical activity had a significantly lower risk of developing Alzheimer's disease. Higher adherence to the Mediterranean diet was associated with slower cognitive decline but not decreased dementia risk.
A team at the University of Pennsylvania School of Medicine has identified a new class of drug-like inhibitors for Alzheimer's disease, specifically targeting tau protein clumping. The discovery, using a large NIH library, reveals 285 compounds with potential interest and focuses on ATPZs that effectively block fibril formation.
Researchers at UCI have identified TOMM40 as a gene that increases the risk of developing Alzheimer's disease by twice its presence in healthy individuals. The study also found that those with ApoE-4 are three to eight times more likely to develop the disease, highlighting new potential therapeutic targets.
Scientists believe that molecular chaperones, which help make and manage proteins, are crucial in both cancer and Alzheimer's. Disabling these molecules may lead to effective treatments for both diseases. Researchers are also exploring the potential of increasing their activity to halt disease progression.
A four-decade study of 9,844 participants found that high cholesterol levels in midlife significantly increase the risk of Alzheimer's disease and vascular dementia later in life. Borderline elevated cholesterol levels also raise risk for late-life vascular dementia.
A study has identified key Alzheimer's brain changes in older individuals with little memory impairment, shedding light on the role of amyloid protein in cognitive decline. The findings suggest that asymptomatic older adults may already be in the early stages of Alzheimer's disease.
Elevated levels of ECE-2 enzyme are linked to reduced blood flow in the brain, a hallmark of Alzheimer's disease. The findings suggest that drugs blocking endothelin-1 may also benefit Alzheimer's patients.
Researchers at University of California - Davis Health report that amyloid plaques and bacterial biofilm elicit the same immune response in human cells, leading to chronic inflammation that damages neurons. The study identifies a protein called TLR-2 as controlling this response.
A study found that a close caregiver relationship can slow Alzheimer's disease progression by retaining more cognitive function and functional abilities over time. Patients with close caregivers scored better on cognitive tests and retained more of their brain function compared to those without close relationships.
A multicenter study found that cerebrospinal fluid biomarkers Aβ42, T-tau, and P-tau can accurately identify patients with mild cognitive impairment who will progress to Alzheimer's disease. The study used a large group of patients with MCI and followed them for at least 2 years or until symptoms progressed.
A study by researchers at Albert Einstein College of Medicine has identified a peptide called humanin that improves insulin action and lowers blood glucose levels in diabetic rodents. Humanin also protects nerve cells from death associated with Alzheimer's and other brain diseases.
Researchers at UC Irvine have found that neural stem cells can rescue memory in mice with advanced Alzheimer's disease by secreting a protein called BDNF, which creates new neural connections. This study provides hope for a potential treatment for the leading cause of elderly dementia.
Researchers at The Hebrew University of Jerusalem discovered a promising approach to treat Alzheimer's disease in individuals with a mutated gene that accelerates disease progression. They found that the mutated enzyme protein damages its protective tail, leading to increased risk and rapid disease progression.
Research published in Neurology suggests that intravenous immunoglobulin (IVIg) treatments may reduce the risk of Alzheimer's disease by targeting beta-amyloid plaques. The study analyzed data from over 847,000 patients and found a 42% lower risk of developing Alzheimer's among those who received IVIg.
Researchers tested individuals with a parent with Alzheimer's disease and found that learning their genetic risk did not result in lasting psychological harm. Genetic counseling helped put the test results into context, reducing distress levels.
Researchers found that vitamin D3 and synthetic curcuminoids can stimulate the immune system to clear brain amyloid beta, a hallmark of Alzheimer's disease. The study suggests combining these nutrients may be more effective for individual patients.
A randomized trial found that disclosing genetic risk information to adult children of patients with Alzheimer's disease did not result in significant short-term psychological distress. Participants who learned they were APOE ε4 negative experienced considerable relief, while those who learned they were APOE ε4 positive showed no more ...
Dimebolin treatment causes an acute increase in brain beta amyloid levels, contradicting its potential as a clinically beneficial Alzheimer's drug. Despite this, the treatment still improves cognitive function in aged rodents and people suffering from mild to moderate Alzheimer's.
Researchers found that low scores on a memory recall test and low glucose metabolism in brain regions can predict a 15-fold greater risk of developing Alzheimer's disease. The study used cognitive tests and brain scans to identify early warning signs of the debilitating disease.
Researchers found that a 'heart healthy' diet, rich in whole grains, vegetables, low-fat dairy, and nuts, may slow cognitive decline. Ongoing moderate physical activity was also associated with improved cognitive function in older adults.
A new Mayo Clinic study found that clinical criteria for mild cognitive impairment are better at predicting Alzheimer's disease than a single memory test. The study identified individuals aged 70-79 years who were cognitively normal or had slight memory impairment as being most likely to develop Alzheimer's disease.
Researchers have identified a combination of brain imaging, memory tests, and protein analysis that can accurately diagnose early-stage Alzheimer's disease. The study used data from the ADNI initiative and found that combining these methods resulted in classification accuracy rates of up to 95.7%.
A study found that a drug similar to one used for rheumatoid arthritis and psoriasis can rescue memory in mice with Alzheimer's symptoms. The drug, PMX205, prevented inflammation in brain regions with amyloid plaques, which accelerates neuron damage.
Researchers at UCLA have developed a method to measure the amount of amyloid beta absorbed by immune cells in the blood, which may help predict Alzheimer's risk. The study found that patients with Alzheimer's disease showed lower uptake of amyloid beta compared to healthy controls.
Research shows a significant increase in people with Alzheimer's and dementia among the 'oldest old', aged 90+, in Europe. The prevalence of dementia standardized on the Italian population was 22.9%, with higher rates in women, increasing with advancing age.
The Alzheimer's Association honored six researchers with lifetime achievement awards for their pioneering work in advancing Alzheimer's research. The awards acknowledged significant advancements in anti-dementia drug therapies and early detection, paving the way for defeating the disease.
Two studies found a strong association between PTSD and increased Alzheimer's risk, but moderate alcohol consumption was shown to lower this risk. Adults also had limited knowledge about the relationship between heart health and brain health.
GUMC researchers discover that a gamma secretase inhibitor can reduce neuronal loss and protect against motor and cognitive deficits in animal models of traumatic brain injury. This finding supports the connection between Alzheimer's disease and traumatic brain injury, suggesting novel therapeutic targets.
Two large studies using DHA showed mixed results, with no benefit in people with mild to moderate Alzheimer's but a positive result in healthy older adults. The findings highlight the need for earlier detection and diagnosis of Alzheimer's disease, as well as further research on genetic interactions.
A new study suggests that partnering with local physicians, conducting educational seminars, and utilizing community outreach are effective tools in recruiting people for Alzheimer's clinical studies. In contrast, patient registries and internet recruiting were found to be less successful strategies. The study also explores the importa...
Researchers at Mount Sinai School of Medicine have found that a natural compound called NIC5-15 may be a safe and effective treatment for mild to moderate Alzheimer's disease. The preliminary findings suggest that NIC5-15 can prevent the formation of beta-amyloid plaque, a key factor in cognitive decline.
A doctor's positive attitude to Alzheimer's diagnosis and their personal relationships with support services are powerful enablers for early diagnosis. However, barriers include differing health priorities, fear of damaging the doctor-patient relationship, and difficulties in referring patients to support services. GPs need education o...
A Mayo Clinic study has developed a framework for MRI-based differential diagnosis of Alzheimer's disease, frontotemporal lobar degeneration, and Lewy body disease. The 'STructural Abnormality iNDex' or STAND-Map framework predicts an accurate pathological diagnosis 75 to 80 percent of the time.
Researchers found that women with higher language scores had a lower risk of developing Alzheimer's disease, despite having hallmark signs of the disease. The study suggested that mental abilities at age 20 may be indicative of a brain better able to cope with diseases later in life.
Research studies by Saint Louis University suggest that inflammation may trigger Alzheimer's disease. Indomethacin, an anti-inflammatory medication, could hold promise as a treatment by protecting the LRP pump that regulates amyloid beta protein accumulation in the brain.
Most cognitive tests are ineffective in distinguishing between Alzheimer's and vascular dementia, with only two tests - Emotional Recognition Task and Delayed Story Recall - showing promise. Researchers emphasize the need for a comprehensive approach to diagnosis, combining multiple measures for accurate identification.
Researchers at Stanford University School of Medicine have identified a wide range of antibodies in healthy people and Alzheimer's patients that target protein aggregates, including those found in plaques. These findings suggest that these antibodies may play a role in slowing or preventing the progression of Alzheimer's disease.
Researchers at the University of South Florida found that caffeine significantly decreased abnormal levels of beta amyloid protein in the brains and blood of Alzheimer's mice, reversing their memory impairment. Caffeine administered to elderly non-demented humans also affects their blood levels of β-amyloid.
A study by Rhode Island Hospital researchers found a substantial link between increased levels of nitrates in the environment and food with increased deaths from diseases such as Alzheimer's, diabetes mellitus, and Parkinson's. The study suggests that reducing nitrate levels in fertilizer and water, detoxifying food and water, may help...
A new study found that blood stem cell growth factor (GCSF) reversed memory impairment in mice with Alzheimer's disease by reducing beta amyloid deposits and promoting new neuron production. The treatment showed promising results in both bone marrow and brain, offering a potential therapy for the disease.
A UCLA psychologist's study reveals that people with very mild Alzheimer's disease have trouble focusing on what's most important. They recall an average of just 2.8 words out of 12, with a reduced ability to be selective in recalling high-value words.
A five-year study funded by the National Institutes of Health will examine the impact of cataract surgery on everyday life for people with dementia. Researchers aim to document how restored vision improves daily tasks and overall well-being.
Scientists have made significant discoveries in the fight against muscular dystrophy, identifying a potential gene therapy approach to overexpress Galgt2 protein. In another breakthrough, researchers have identified a stromal marker for breast cancer progression, highlighting the importance of examining stroma PDGF receptor expression ...
Researchers have discovered a new link between soluble amyloid beta protein and synaptic injury in Alzheimer's disease. The study reveals that amyloid beta enhances long-term synaptic depression through altered glutamate uptake at hippocampal synapses.
A recent study has identified biomarkers in cerebrospinal fluid that can reveal Alzheimer's disease at a very early stage, even in patients with minimal memory impairment. The findings suggest that these biomarkers can predict the risk of deterioration by 27 times higher than the control group.
A new x-ray imaging technique, diffraction-enhanced imaging (DEI), has been developed to visualize individual amyloid beta plaques in the brain. The study successfully images these tiny structures in a mouse model of Alzheimer's disease, providing promising clues for early diagnosis and treatment.
A fully automated procedure measuring brain structures is effective in predicting the progression from mild cognitive impairment to Alzheimer's disease. The technique can be used in clinics to measure brain atrophy and help physicians predict decline in MCI patients.
A recent study published by the American Academy of Neurology found that individuals with depression and mild cognitive impairment are at a higher risk of developing Alzheimer's disease. The study also showed that taking donepezil may delay progression to Alzheimer's for those with memory problems.
A new study by researchers at Rush University Medical Center found that possessing a greater purpose in life is associated with lower mortality rates among older adults. The study used data from 1,238 community-dwelling elderly participants and found a substantially reduced risk of mortality among those with high purpose in life.
Researchers found that microglial cell degeneration contributes to loss of neurons and dementia, contradicting the popular neuro-inflammation theory. The study suggests that anti-inflammatory drugs may not be effective in fighting dementia.
A UCLA study reveals that depression may increase the risk of developing Alzheimer's disease in individuals with mild cognitive impairment. Researchers also found that the medication donepezil can delay the progression of Alzheimer's in depressed individuals with memory problems.
Researchers have detected a peptide in cerebrospinal fluid that can indicate the onset of Alzheimer's disease, potentially allowing for earlier diagnosis and treatment. This discovery raises new opportunities for combating the disease, which currently requires treatments to be started after significant brain damage has occurred.
A recent study published in Archives of Neurology found that cognitive impairment is associated with reduced survival rates among both white and African American older adults. The research, which followed 1,715 participants over an average of 4.7 years, showed that individuals with mild cognitive impairment or Alzheimer's disease had s...
A new study by Rush University Medical Center researchers found that cognitive impairment is associated with reduced survival among both African-Americans and whites. The study, published in Archives of Neurology, showed that participants with mild cognitive impairment had a 50% increased risk of death compared to those without cogniti...
Researchers at Natura Therapeutics and the University of South Florida are studying the green tea compound TeaMem, which may block a key process in Alzheimer's development. The NIH grant will investigate TeaMem's role in preventing AD pathology and cognitive impairment.